Design
Editorial
Answers are grounded in this paper and cite their sources.
The editorial introduces the new EHJ – Quality of Care and Clinical Outcomes journal, highlighting its role in addressing the need for outcomes research and quality of care studies in cardiovascular medicine.
The editors of the ESC Journal Family are welcoming its newest member, the EHJ – Quality of Care and Clinical Outcomes, and are looking forward to working with its editor-in-chief and team. The present editorial by the chairman of the publications committee of the European Society of Cardiology outlines its place within the ESC Journal Family and the gaps it will close in the educational program of the European Society of Cardiology. The ESC Journal Family has grown impressively over the last decade in size, quality, and impact.1 Currently, the European Society of Cardiology publishes 12 journals. These journals cover everything from general cardiology, the flagship journal the European Heart Journal (EHJ), to many specialty journals of cardiovascular medicine (Figure 1). In addition, the journal of our surgical colleagues, the European Journal of Thoracic and Cardiovascular Surgery, has been affiliated with the ESC Journal Family.2 As such, the ESC Journal Family is the largest group of cardiovascular journals, outnumbering its US competitors. The growing ESC Journal Family today works closely together and now also cooperates intensely with EuroIntervention, the official journal of the European Association of Percutaneous Cardiac Interventions (EAPCI), and has welcomed in 2012 the EHJ – Acute Cardiac Care, the official journal of the European Association of Acute Cardiac Care. At the beginning of 2014, the European Journal of Cardio-Thoracic Surgery has been associated with the Family and in 2014, the EHJ – Cardiovascular Pharmacotherapy & Drug Therapy. In 2015, we are pleased to welcome the EHJ Quality of Care and Clinical Outcomes. Thus, as of now 14 ESC journals cover the entire spectrum of cardiovascular medicine and surgery. Most recently, the ESC approved several new journals covering fields which had been neglected so far. These journals are for acute cardiac care,3 pharmacotherapy (EHJ Cardiovascular Pharmacotherapy),4 and now the new journal EHJ Quality of Care and Clinical Outcomes. An important feature of the ESC Journal Family is the manuscript transfer system, which was implemented by the current editorial team in 2009.5 With this system, the editors of the EHJ can recommend a transfer to one of the specialty journals to a submitting author, where appropriate. Furthermore, this system also allows direct transfer of manuscripts that have already undergone peer review, if recommended by the consulted experts or the editors involved. As such, papers with 2–3 obtained reviews can be offered to the editor of a suitable specialty journal for consideration. In general, transfer decisions are reached if the manuscript appears too technical or specialized for a broader audience, or does not reach the priority for a high impact journal. If the editor of a sister journal agrees to consider the manuscript based on the available reviews, the authors are given the opportunity to resubmit a revised version based on the comments and suggestions of the reviewers of the EHJ. Such an offer saves the authors time and unnecessary work, but also avoids that in the next round, new reviewers will raise different issues and delay the publication of the results further. As a consequence, transferred manuscripts are published faster within the ESC Journal Family. It is interesting to note that transferred papers tend to be better cited than those directly submitted to a specialty journal.6 Last year the European Heart Journal transferred 219 manuscripts to its sister journals (Figure 2). A similar transfer will be coming into effect for the EHJ Quality of Care and Clinical Outcomes, and the editors of the European Heart Journal are looking forward to working with Adam Timmis and his team on this. During 2014, 741 manuscripts were flagged for transfer by the EHJ and 419 were accepted by the sister journal editors and eventually 55 accepted after revision. The ESC Journals are proud that they could improve their quality, influence, and impact over the past years. Of note, these measures are not strictly comparable;7 indeed, journals aim to satisfy the interests of their readers and also want to contribute to the scientific process. The readers' interest or the influence of a journal is reflected in the number of subscriptions, be it individual or institutional, and most importantly by the number of manuscript downloads. The European Heart Journal is proud that the number of institutional subscriptions increased by 25% over the last years, and that the number of downloads reached almost 6 million in 2014.1 Thus, many papers, reviews, and in particular guidelines relevant for the daily clinical practice of many physicians and cardiologists around the world are accessed in large numbers. A similar trend has been observed among the most successful specialty journals and we certainly hope that the new EHJ Quality of Care and Clinical Outcomes will also find the interest of our readers. Another key success factor of scientific journals—distinctly different from influence—is the impact factor, which mainly reflects its importance for scientists and clinicians with research interests. Today, this is the most visible measure of quality, although it reflects only one aspect of a scientific journal. Only colleagues involved in research affect the impact factor when they cite a paper relevant for their own work. Over the years, the European Heart Journal has experienced a remarkable growth in impact and influence. Thanks to the ESC Journal Family, many sister journals could take advantage of this momentum and have also increased their influence and impact (Figure 3). Impact factors of members of the ESC Journal Family over time. Given the increasing number of scientific journals worldwide and in the cardiovascular field in particular, one might venture to ask if we really need new journals. One might argue that there are enough journals available already. On the other hand, one must consider that medicine has experienced an impressive growth in knowledge, drugs, and technologies in the last decades. As a result, this has produced many specialties and subspecialties, particularly in cardiovascular medicine and research. As such in cardiology, the scientific community has split into an increasing number of distinct areas of interest and competence. Most of these scientific communities work on highly specialized topics and often use their own expressions and language. Therefore, distinct products addressing the needs of such communities have become important. With the EHJ Quality of Care and Clinical Outcomes, the European Society of Cardiology wishes to close the gap in this often neglected but increasingly important area of interest. The bumpy road to evidence8 begins with basic science, early clinical trials, and eventually large randomized studies. Once a novel treatment strategy is approved, it is then usually—depending on the level of evidence achieved—implemented into guideline recommendations such as the recently published ones on hypertrophic cardiomyopathy,9 aortic disease,10 or revascularization.11 In clinical medicine, the process does not stop there. Only if the evidence is moved into clinical practice, do patients benefit from scientific discoveries. To ascertain this important process, quality-of-care studies are required. Of note, for many years, now the European Society of Cardiology has launched registry projects assessing the use of guideline-recommended therapies (Figure 4;12–16). The publication of such data allows for specific interventions in areas where guideline implementation is insufficient. Beyond that, in this day and age, it is essential that the cardiovascular community convince politicians and the society at large that their measures are not only effective, but also being appropriately used in patients in need. The educational circle: from basic discoveries to clinical trials, guideline recommendations and outcomes, as well as quality research. Precisely because of this and due to the increasing health costs, evidence alone does not suffice—treatments also have to be cost-effective to be politically acceptable. This is a research area that is underdeveloped in cardiovascular medicine, in spite of the fact that this specialty has produced highly effective, but similarly expensive drugs, implants, and devices. The more important it is that a product for this field is provided. The European Society of Cardiology wishes to take the lead by establishing the novel journal EHJ – Quality of Care and Clinical Outcomes. Finally, we need to know what we truly achieve with the evidence cardiovascular research provides to practicing physicians. Such data cannot be derived from randomized trials alone, as they commonly exclude many patients seen in everyday practice. Real-world data are as important as results of controlled trials. Outcomes research addresses that need—hence, also in this regard the new journal is filling a gap. In parallel with this scientific initiative, the European Society of Cardiology also opened its offices in Brussels in close vicinity to the European Union, in an attempt to be closer to the political decision process. The leadership of the society felt that it is crucial, as well as to the benefit of Europe at large, to provide political decision makers with objective information on cardiovascular disease and its appropriate management. The new EHJ – Quality of Care and Clinical Outcomes is also expected to fill an essential gap in this context.
No takes yet. Share an insight, caveat, or question.
Thomas F. Lüscher (2015) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: